Cite
HARVARD Citation
O'Reilly, M. et al. (2022). Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46–62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease. British journal of haematology. pp. 40-44. [Online].